Protein Design Labs (PDLI): Stock strong

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Protein Design Labs (PDLI): Stock strong

An SI Board Since February 1997

Posts	SubjectMarks	Bans	Symbol
407	58	0	PDLI

Emcee: Stanley Cowen	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
57	Thanks, John; I'm margined on this stock but hope I can hold as I believe z	Dulane U. Ponder	-	1/28/1998
56	There appears to be some confusion over Thymoglobulin. Still there is a firm su	John S. Sturges	-	1/27/1998
55	This stock is really taking a beating today. Any more news? Can't believe	Dulane U. Ponder	-	1/27/1998
54	Further information on PDLI selloff. Apparently Robertson Stevens inidcated tha	John S. Sturges	-	1/26/1998
53	I didn't have all the details as to who said what. However their was confus	John S. Sturges	-	1/25/1998
52	John: Interesting..... there's evidence to say that Z plus methotrexate	scaram(o)uche	-	1/25/1998
51	Weakness is buying opportunity. Zenapax is flying off the shelf. One firm has c	John S. Sturges	-	1/24/1998
50	I can't be of much help on pricing the loss of cyclosporin to Novartis if I	John S. Sturges	-	12/23/1997
49	All, if PDLI threatens Novartis' Cyclosporin, should some discount be consi	John Metcalf	-	12/22/1997
48	Since you understand the technical side of PDLI's work you should go to the	John S. Sturges	-	12/17/1997
47	Michael: Yeah. I knew that....... once, long before I forgot it. :-) Also	scaram(o)uche	-	12/17/1997
46	You are correct! OST 577 was bought from Novartis for $5Million when they did n	John S. Sturges	-	12/16/1997
45	Glad to have your here. Now, at least my posts won't lose anything in the t	Michael Olin	-	12/15/1997
44	My thanks to you Michael for introducing me to Silicon Investor. A great servic	John S. Sturges	-	12/15/1997
43	Monoclonal antibody technology, Phase III, low-valuation. Take a look at Altare	Juergen	-	12/14/1997
42	Thanks for the info, John. I just thought it was an interesting buy for Soros.	Dulane U. Ponder	-	12/14/1997
41	What I can tell you is that Soros bought on the advice of CIBC Oppenheimer'	John S. Sturges	-	12/14/1997
40	I've traded PDLI profitably on several occasions. Most recently I sold at	Dulane U. Ponder	-	12/13/1997
39	The long explanation is that the phase II study was flawed and failed to enroll	John S. Sturges	-	12/13/1997
38	Michael: thanks! Rick [EOM]	scaram(o)uche	-	12/12/1997
37	Rick, I'm not so much up on the science as I am on the drug licensing proc	Michael Olin	-	12/12/1997
36	Michael: Thanks. To answer the question, which you did, one needs to know the	scaram(o)uche	-	12/12/1997
35	The immune complex disease was not related to, and should not be a problem with	Michael Olin	-	12/12/1997
34	Michael: No problems with the returned compounds? What do you call immune com	scaram(o)uche	-	12/11/1997
33	The stock movement has nothing to do with the approval. Most of the movement is	Michael Olin	-	12/11/1997

Go to reply# or date (mm/dd/yy):